Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance:A Multicenter Retrospective Study

NCT06202599 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06202599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06202599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance:A Multicenter Retrospective Study
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Completed
Start date
November 25, 2021
Completion date
November 15, 2023
Enrollment
124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone sarcoma, refractory tumor, soft tissue sarcoma